GlaxoSmithKline Pharmaceuticals Ltd

Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT® (fingolimod)

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Multiple sclerosis, Disease, Seizure, News, Castleman disease, Infection, Associate, Hospital, Non-Hodgkin lymphoma, Blood, GlaxoSmithKline Pharmaceuticals Ltd, ODT, University, Person, Lymphoma, RRMS, Liver injury, MS, Posterior reversible encephalopathy syndrome, Headache, QT interval, Melanoma, Status epilepticus, Safety, Blood pressure, Macular edema, Squamous cell carcinoma, FDA, MD, Risk, Angioedema, Sinusitis, Pediatrics, Hives, Vaccine, Bradycardia, Rash, Tongue, Children's Hospital Los Angeles, AV, Water, Patient, History, Medicine, Neurology, Abdominal pain, Stroke, Back pain, Arrhythmia, MRI, Hypersensitivity, Myocardial infarction, Cough, Incidence, Diarrhea, Pain, Excipient, Food, Generic drug, Pharmaceutical industry, Health insurance, Medical device, Fingolimod, Cycle

To find out more about TASCENSO ODT and Cycle Vita please visit www.tascenso.com and www.cyclevita.life respectively.

Key Points: 
  • To find out more about TASCENSO ODT and Cycle Vita please visit www.tascenso.com and www.cyclevita.life respectively.
  • Due to a risk for bradyarrhythmia and AV blocks patients should be monitored during TASCENSO ODT treatment initiation.
  • Use of live attenuated vaccines during, and for 2 months after stopping TASCENSO ODT, should be avoided.
  • To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals Ltd at 1-888-533-1625 or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch .

MGC Pharmaceuticals Successfully Developed Herbal-inspired Products for Treatment of Long COVID and COVID-19

Retrieved on: 
Wednesday, September 21, 2022
Respiratory rate, ASX, MXC, Time, Safety, GlaxoSmithKline Pharmaceuticals Ltd, COVID-19, Accessibility, Company, COVID, Patient, LSE, MGC, OTC, CEO, Confusion, Headache, Herbal medicine, Gavi, Budget, Pharmaceutical industry, Hospital, Weakness, Pharmacokinetics, Long COVID, Cough, Shortness of breath

Researchers around the world still do not know what exactly causes the Post-Acute COVID Syndrome (Long COVID) symptoms.

Key Points: 
  • Researchers around the world still do not know what exactly causes the Post-Acute COVID Syndrome (Long COVID) symptoms.
  • While the number of new COVID-19 and variant cases is on the decline, there are tens of millions of people around the world suffering from Long COVID symptoms over extended periods of time.
  • MGC Pharmaceuticals, along with Swiss Pharmacan, have developed two clinically tested herbal-based products that ameliorate the more troublesome symptoms of Long COVID and COVID-19.
  • The first product is ArtemiC Support, used in treating Long COVID.

ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of Directors

Retrieved on: 
Wednesday, January 19, 2022
Duke University School of Medicine, Patient, Accounting, Brigham, Associate, Hypoglycemia, LinkedIn, Amylin Pharmaceuticals, SAN, Hypertension, Board of directors, Cell encapsulation, CRISPR Therapeutics, Protein, LLP, W. L. Gore & Associates, Leadership, Virtual College of Biotechnology, University of Saskatchewan, Regenerative medicine, History of the College of William & Mary, View, Duke University Hospital, Industry, Therapy, Brigham and Women's Hospital, Diabetes, Company, Drug development, GlaxoSmithKline Pharmaceuticals Ltd, Hospital, University, Multimedia, Type 2 diabetes, Potency (pharmacology), Risk, PricewaterhouseCoopers, Twitter, College, Senior, Board, Pharmaceutical industry, Management, Exenatide, Facebook, Operation, Endocrinology

"We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.

Key Points: 
  • "We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.
  • "I am excited to lead the finance team as we pursue significant clinical and growth opportunities to create increased value across our pipeline."
  • Previously, Ms. Levin was Chief Financial Officer at Bird Rock Bio, a clinical-stage bio-pharmaceutical company focused on the treatment of fibrotic, metabolic and inflammatory diseases.
  • Prior to Nano Precision Medical, Dr. Porter was Chief Medical Officer for Eiger Biopharmaceuticals, Inc. and Dance Biopharma, Inc. (now Aerami Therapeutics).

Code Biotherapeutics Appoints Erin Brubaker as Chief Operating Officer

Retrieved on: 
Thursday, December 2, 2021
Health, Biotechnology, Patient, Information technology, Board of directors, Company, Compliance, Lists of diseases, University, COO, Program, Protalix BioTherapeutics, Franklin & Marshall College, R, DNA, Biotechnology, Duchenne muscular dystrophy, Wharton School of the University of Pennsylvania, Marshall College, Corporate development, Science, Transformational leadership, Executive, GlaxoSmithKline Pharmaceuticals Ltd, Vaccine, Management

Code Biotherapeutics, Inc., a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announces the appointment of Erin Brubaker as Chief Operating Officer, effective immediately.

Key Points: 
  • Code Biotherapeutics, Inc., a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announces the appointment of Erin Brubaker as Chief Operating Officer, effective immediately.
  • I am thrilled to welcome Erin to our Executive team, said Code Bio Chairman, Chief Executive Officer, and Co-Founder Brian P. McVeigh.
  • Most recently she served as Vice President Corporate Development at Passage Bio, a fully integrated gene therapy company.
  • Code Bio has a unique opportunity to deliver targeted, non-viral gene therapies with its proprietary 3DNA delivery platform, said Ms. Brubaker.

TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors

Retrieved on: 
Wednesday, April 15, 2020
Medical specialties, Medicine, Health, Immunology, Immune-related response criteria, Oncology, Cancer immunotherapy, Ipilimumab, CTLA-4, GlaxoSmithKline Pharmaceuticals Ltd, GlaxoSmithKline

An immuno-oncology pioneer with broad business and scientific expertise, Dr. Hoos is recognized for launching the field through development of the anti-CTLA-4 ipilimumab, the first FDA-approved checkpoint immunotherapy.

Key Points: 
  • An immuno-oncology pioneer with broad business and scientific expertise, Dr. Hoos is recognized for launching the field through development of the anti-CTLA-4 ipilimumab, the first FDA-approved checkpoint immunotherapy.
  • "Axels vision and leadership have had a profound impact on how the industry approaches the discovery and development of immunotherapies.
  • Dr. Axel Hoos is Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK).
  • "Our goal in immunotherapy is to create transformational medicines for patients through innovation and by challenging or expanding established scientific concepts," said Dr. Hoos.

China Lamivudine Market Report 2018: Market is Dominated by GSK, Wellcome Foundation, Anhui Biochem Bio-Pharmaceutical and Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock

Retrieved on: 
Wednesday, September 26, 2018
Health, RTT, Medicine, Hepatotoxins, Lamivudine, Nucleosides, GlaxoSmithKline, HIV/AIDS in China, GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceutical industry in China, Hepatitis, Pharmaceutical industry

At the end of 2017, there were more than 700,000 registered HIV-infected persons and AIDS patients in China.

Key Points: 
  • At the end of 2017, there were more than 700,000 registered HIV-infected persons and AIDS patients in China.
  • Lamivudine is a major drug against the hepatitis B virus and AIDS in China.
  • The market is dominated by GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd., Wellcome Foundation, Anhui Biochem Bio-Pharmaceutical Co., Ltd. and Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd. has the largest market share.
  • Considering the large number of hepatitis B and AIDS patients in China, it is expected that the market size of China's Lamivudine market will continue to grow.